Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 12/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509795 | 1.00 | MAPK1 (0.72) | MAPK1L3MBTL1MAPTPOLBJAK2 | |
| SCHEMBL31717653 | 0.87 | MAPK1 (0.78) | MAPK1L3MBTL1MAPTPOLBJAK2 | |
| SCHEMBL30776873 | 0.87 | MAPT (0.78) | MAPK1L3MBTL1MAPTPOLBJAK2 | |
| SCHEMBL23675211 | 0.87 | MAPT (0.78) | MAPK1L3MBTL1MAPTPOLBJAK2 | |
| SCHEMBL29565312 | 0.87 | MAPT (0.78) | MAPK1L3MBTL1MAPTPOLBJAK2 | |
| SCHEMBL21811833 | 0.81 | MAPK1 (0.48) | MAPK1L3MBTL1MAPTEGFR | |
| SCHEMBL29244135 | 0.81 | MAPT (0.60) | MAPK1L3MBTL1MAPTPOLBJAK2 | |
| SCHEMBL23675118 | 0.81 | MAPT (0.79) | MAPK1L3MBTL1MAPTPOLBJAK2 | |
| SCHEMBL8233274 | 0.81 | MAPT (0.61) | MAPTAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL29868880 | 0.81 | MAPT (0.79) | MAPK1L3MBTL1MAPTPOLBJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290419-A | Pyridoimidazole derivative, preparation method and application thereof | 成都硕德药业有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-112714765-B | GABA A Receptor ligands | 萨尼奥纳有限责任公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-3849976-B1 | A GABA A RECEPTOR LIGAND | SANIONA AS (DK) | 2022-10-26 | — | — | EP | disclosed |
| US-11396510-B2 | GABAA receptor ligand | SANIONA A/S (DK) | 2022-07-26 | — | — | US | disclosed |
| US-20210332042-A1 | A GABAA Receptor Ligand | SANIONA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210332042-A1 | A GABAA Receptor Ligand | SANIONA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| EP-3849976-A1 | A GABA A RECEPTOR LIGAND | Saniona A/S (DK) | 2021-07-21 | — | — | EP | disclosed |
| CN-112714765-A | GABAAReceptor ligands | 萨尼奥纳有限责任公司 | 2021-04-27 | — | — | CN | disclosed |
| WO-2020053377-A1 | A GABAA RECEPTOR LIGAND | SANIONA A/S (DK) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332042-A1 | A GABAA Receptor Ligand | GABRA2, GABRA6, GABRA5 | MAPK1 4095/4885L3MBTL1 2483/4885MAPT 3030/4885 |
| US-11396510-B2 | GABAA receptor ligand | GABRA2, GABRA3, GABRA6 | MAPK1 4197/4885L3MBTL1 2359/4885MAPT 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.